Solid Tumours Clinical Trials

20 recruiting

Solid Tumours Trials at a Glance

32 actively recruiting trials for solid tumours are listed on ClinicalTrialsFinder across 6 cities in 47 countries. The largest study group is Phase 1 with 23 trials, with the heaviest enrollment activity in Houston, London, and Fairfax. Lead sponsors running solid tumours studies include AstraZeneca, Boehringer Ingelheim, and Cancer Research UK.

Browse solid tumours trials by phase

Treatments under study

About Solid Tumours Clinical Trials

Looking for clinical trials for Solid Tumours? There are currently 20 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Solid Tumours trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Solid Tumours clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 32 trials

Recruiting
Phase 2

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

Solid Tumours
Boehringer Ingelheim430 enrolled88 locationsNCT06581432
Recruiting
Phase 1Phase 2

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

Solid Tumours
AstraZeneca180 enrolled18 locationsNCT07446855
Recruiting
Phase 1

A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it Helps

MelanomaSolid Tumours
Boehringer Ingelheim69 enrolled6 locationsNCT07224425
Recruiting
Phase 1

A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab

Solid Tumours
AstraZeneca40 enrolled19 locationsNCT07391670
Recruiting

A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test

Solid Tumours
Hoffmann-La Roche15,000 enrolled138 locationsNCT04529122
Recruiting
Phase 1Phase 2

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

Solid Tumours
Bristol-Myers Squibb315 enrolled19 locationsNCT07160725
Recruiting
Phase 1

A Phase I Open-Label, Single-Arm, Dose-Escalation Clinical and Pharmacology Study of CCI-001 as Monotherapy and in Combination With Standard Chemotherapy in Patients With Recurrent and/or Metastatic Solid Tumours

Cancer: Recurrent and/or Metastatic Solid Tumours
PharmaMatrix Holdings Ltd70 enrolled1 locationNCT04823897
Recruiting
Phase 1Phase 2

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

Advanced Solid Tumours
Pyxis Oncology, Inc220 enrolled15 locationsNCT06795412
Recruiting
Phase 1

First in Human Study of AZD9592 in Solid Tumors

Advanced Solid Tumours
AstraZeneca403 enrolled50 locationsNCT05647122
Recruiting

Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis

Nausea and VomitingOlanzapineSolid Tumours
Shandong Cancer Hospital and Institute2,000 enrolled1 locationNCT07403370
Recruiting
Phase 1

A Study of EBC-129 in Advanced Solid Tumours

Advanced Solid Tumours
EDDC (Experimental Drug Development Centre), A*STAR Research Entities98 enrolled5 locationsNCT05701527
Recruiting
Phase 1

First in Human Study of SIM0610 in Solid Tumors

Advanced Solid Tumours
Jiangsu Simcere Pharmaceutical Co., Ltd.260 enrolled7 locationsNCT07348211
Recruiting
Phase 1Phase 2

A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours

Solid Tumours
Orion Corporation, Orion Pharma315 enrolled1 locationNCT06725758
Recruiting
Phase 1

A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors

Solid Tumours
AP Biosciences Inc.36 enrolled3 locationsNCT07165067
Recruiting
Phase 1

A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours.

Advanced Solid TumoursSolid Tumours
Race Oncology Ltd53 enrolled5 locationsNCT06815575
Recruiting
Phase 2Phase 3

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

MalignancyMelanomaCancer+7 more
Cancer Research UK30 enrolled27 locationsNCT05770102
Recruiting

Tissue Collection Framework To Improve Outcomes In Solid Tumours

Solid Tumours
Queen Mary University of London3,000 enrolled1 locationNCT03572192
Recruiting
Phase 1Phase 2

A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Advanced Solid Tumours
LaNova Medicines Limited87 enrolled6 locationsNCT06868199
Recruiting
Phase 1

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

SarcomaHNSCCSolid Tumours
Epkin166 enrolled10 locationsNCT06789172
Recruiting
Phase 1Phase 2

A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour

Advanced Malignant Solid Tumours
Shanghai Junshi Bioscience Co., Ltd.374 enrolled1 locationNCT06888830